about
Single-stage bilateral choroid plexectomy for choroid plexus papilloma in a patient presenting with high cerebrospinal fluid outputGlioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaAn integrated genomic analysis of human glioblastoma multiformeIDH1 and IDH2 mutations in gliomasGlioma stem cells promote radioresistance by preferential activation of the DNA damage responseMutations in CIC and FUBP1 contribute to human oligodendrogliomaSubgroup-specific structural variation across 1,000 medulloblastoma genomesThe genetic landscape of the childhood cancer medulloblastomaIdentification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acidA PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancerA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaSensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma.Intraaxial dermoid cyst of the medulla.MRP3: a molecular target for human glioblastoma multiforme immunotherapy.Cerebellopontine angle craniopharyngioma: case report and literature review.Second messenger systems in human gliomas.Phase II trial of temozolomide in patients with progressive low-grade glioma.Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma.Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study.A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant gliomac-Myc is required for maintenance of glioma cancer stem cells.Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.Targeting A20 decreases glioma stem cell survival and tumor growth.The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growthThe genetic landscape of anaplastic astrocytoma.Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasMismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant gliomaClinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesisEGFRvIII-targeted vaccination therapy of malignant glioma.Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma.
P50
Q22336974-C36926A8-FAE5-472F-B201-BC61499E49B3Q24628857-9BB3C7EA-586D-4FFC-947A-AB91420D06F6Q24644727-9C2C1255-CAAD-4CD0-BAD1-28F0FE29EE72Q24648860-FD9B4C67-9683-4FC1-89AD-17DCDB715A5DQ24648948-A2B3F55E-27D4-4A29-87EA-6FBD5F26F580Q27860541-442C5CA4-FE3D-4EE8-AAE7-0334340509F6Q28244895-F7F6E061-2F8A-41BF-996E-C5CBB6A9AC56Q28271811-5239EC03-2F0E-496A-A36E-60800AC69366Q28301196-FF12745C-1940-4781-807D-219A84B48173Q28307014-454E12E3-B5FE-4FFE-96BF-3A829A7EB738Q28485246-BE0BFFE5-E265-4242-9AA3-3C0D43CDF215Q28731711-94448A5D-ED5B-4B27-9D49-8BE9A18D7361Q30491742-574F3E70-9EA8-470E-8684-00720238A73DQ30620069-CE9FD66D-6ED0-4B7B-B9D2-44D5CBCA7E5DQ30988770-DA04084D-D9F5-4AB6-874B-853A62CA756FQ31104404-B3F37D8E-66D0-4CB3-8A51-77877E3FD79DQ33301928-8B0C35F0-A1BE-4024-B74A-B7D5C74E59A7Q33346531-18C8B5DA-2B3E-4A0F-B130-B201FFB19C06Q33369628-1383A6DF-CCA6-416A-BC07-556266FD2A7EQ33370229-FD87081C-2D25-4771-87EF-DD340F687C31Q33370457-14AF284A-C311-40D8-B71C-8D829D25273BQ33372861-EDFFBEE2-7396-4823-82C4-F25A9BBD1C40Q33378699-13DF10B5-B3EA-45DF-A261-56ACF0338DEAQ33383721-7A2076B6-00C6-4E76-A5D1-D6C70FE7EB57Q33384269-623C0F03-E789-407C-AA7B-6A0BB2BFB039Q33385645-E9742C2A-5509-4976-A287-5B11FB9D19A5Q33397569-188A64E7-BFB9-4DD6-97A1-F41943E35686Q33399939-F77F8E8B-FB86-4D63-B700-3C81187A6ABAQ33534629-0276757D-5E8B-4209-974E-4AD7B0DCE96FQ33674720-00DB7F28-9BBF-41FF-B614-4064F6B06D41Q33674790-6CB5277F-AB06-40F8-89F7-B3EE3110B11FQ33688888-4DD46094-8174-47AA-9B36-2FBA85035216Q33688915-327BF1B6-04BA-4C06-A3F3-99F52E3C2EF5Q33696343-A939CBDD-C236-4FA1-8007-218A8DDAAFE8Q33705446-DB1D2DC2-7A74-48D0-A05F-B0025DD45C62Q33713587-86DC871A-1766-4D86-8CFF-EB34A0310BEEQ33747609-82C957DC-1DAE-48B0-BBF4-D46811999B03Q33750767-D5015AC0-786A-4E8A-866A-A03CF8E9C0A6Q33758459-8432624A-ECDF-40E0-866B-CD4533435021Q33788867-33A84171-93C1-41A3-AD9D-70D327CF1CE4
P50
name
Roger E McLendon
@en
type
label
Roger E McLendon
@en
prefLabel
Roger E McLendon
@en